Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 50: 2376-2378, 2004; 10.1373/clinchem.2004.036137
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berger, M.
Right arrow Articles by Lindner, T. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berger, M.
Right arrow Articles by Lindner, T. H.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 2004;50:2376-2378.)
© 2004 American Association for Clinical Chemistry, Inc.


Technical Briefs

Alternative Approach for Rapid and Reliable Single-Nucleotide Polymorphism Typing with Double Restriction Mutagenesis Primer PCR

Mario Berger1, Silke Zschemisch1, Berthold Hocher2,3, Detlev Mönks1, Torsten Slowinski2, Horst Halle4, Christoph Wanner1, Ulrich Walter5 and Tom H. Lindner1,a

1 Department of Medicine, Division of Nephrology, University Clinic, Würzburg, Germany
2 Center for Cardiovascular Research/Institute of Pharmacology and Toxicology, University Clinic Charité, Berlin, Germany
3 Division of Nephrology and Hypertension, Inselspital, University of Berne, Berne, Switzerland
4 Department of Obstetrics and Gynecology, University Clinic Charité, Berlin, Germany
5 Department of Clinical Biochemistry and Pathobiochemistry, University of Würzburg, Würzburg, Germany

aaddress correspondence to this author at: Division of Nephrology, Department of Medicine, University of Würzburg, Josef-Schneider-Strasse 2, 97080 Würzburg, Germany; fax 49-931-201-36502, e-mail tom.lindner@mail.uni-wuerzburg.de

The first 300 words of the full text of this article appear below.

Complex disorders such as type 2 diabetes or coronary heart disease are of major public interest because they affect millions of individuals. To unravel the genetic background of those traits, genome-wide linkage scans with microsatellite markers have been performed, followed by association studies of single-nucleotide polymorphisms (SNPs) in the identified candidate regions. High-throughput SNP typing technologies such as matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (1), pyrosequencing (2), TaqMan-based allelic discrimination (3), and others (4)(5)(6)(7)(8) can be used for that approach. However, many smaller and medium-throughput laboratories have no access to rapid, reliable, universal, and cost-effective SNP typing methods. The establishment of such a technique therefore has a high priority.

We have developed a simple and inexpensive two-step method for SNP detection (PCR followed by modified restriction digestion), called double restriction mutagenesis primer PCR (DRMP-PCR). Our approach is based on the introduction of two restriction sites in one of the two PCR primers (mutagenesis reverse primer). This method appears to represent an improvement over older techniques such as PCR–primer-introduced restriction analysis (PIRA) (9) with respect to both specificity and reliability. In addition, we have generated a PERL-based computer program that provides the restriction enzymes and necessary mutagenesis sequences for primer design.

Our method allows detection of SNPs by use of fluorescence scanning sequencers and automated automatic allele calling. The forward primer must therefore have a 5' fluorescence label (hexachloro-6-carboxyfluorescein, 6-carboxyfluorescein, or others) but does not undergo any additional changes. The 3' end of the reverse primer is positioned next to the SNP and forms a restriction site together with one of the two SNP alleles (Fig. 1A ). In most cases, one or two bases of the 3' end of the primer . . . [Full Text of this Article]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.